Could Clovis Oncology Stock Be Gearing Up For Its Next Move?
Clovis Oncology Inc. (NASDAQ: CLVS) is gearing up to present this week at the American Society of Clinical Oncology annual meeting, which runs June 4-8.
The company is expected to report updated Phase 1b results on Lucitanib and Opdivo in patients with advanced solid tumors.